Immunic(US:IMUX) Prnewswire·2024-08-28 10:30Core Insights - Immunic, Inc. is hosting a Multiple Sclerosis (MS) Research and Development Day on September 10, 2024, to discuss its lead asset, vidofludimus calcium (IMU-838), which is being developed for relapsing and progressive MS patients [1] - The company will participate in several scientific and investor conferences in September, including the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 18-20, where data on vidofludimus calcium will be presented [1][2] - Vidofludimus calcium is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive MS, showing therapeutic activity in previous trials [6] Company Events - The MS R&D Day will feature Immunic's management and renowned experts discussing the MS landscape and the potential of vidofludimus calcium [1] - The company will present data on vidofludimus calcium in an oral presentation and three ePosters at the ECTRIMS conference [1][2] - Additional presentations will occur at the DMDG 50th Open Meeting and the 20th International Celiac Disease Symposium, showcasing data from various clinical trials [4][5] Product Development - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and anti-inflammatory properties [6] - IMU-856, another product targeting Sirtuin 6 (SIRT6), is in preparations for a phase 2 clinical trial aimed at treating celiac disease [6] - The company is also developing IMU-381, a next-generation molecule for gastrointestinal diseases, currently in preclinical testing [6]